Metabolic heterogeneity in gliomas, particularly glioblastoma (GBM), has emerged as a critical area of research, revealing significant differences in cellular metabolism across various tumor microenvironments. A study highlighted the distinct lipid metabolism profiles between glioblastoma stem cells and non-stem cells, demonstrating that lipid processing gene expression and total lipid content varied markedly among different cellular niches within the same tumor. Specifically, the research found that hypoxic regions, such as organoid cores and pseudopalisading areas, exhibited enriched lipid content, which was linked to the upregulation of hypoxia-inducible lipid droplet-associated (HILPDA) gene expression. This differential expression was not observed in lower-grade brain tumors, underscoring the unique metabolic adaptations of GBM cells in response to their microenvironment (ref: Shakya doi.org/10.1186/s40478-021-01205-7/). The implications of these findings suggest that targeting lipid metabolism could be a potential therapeutic strategy, as the metabolic profiles of glioma cells may influence their growth and response to treatment. Furthermore, understanding the metabolic landscape of gliomas could provide insights into tumor progression and the development of resistance to therapies, highlighting the need for personalized treatment approaches based on metabolic characteristics.